PSIC will be the first Saudi pharmaceutical company to produce an extensive range of drugs developed by lipids nanotechnology such as:
- Anticancer Liposomal Drugs
- Antifungal Liposomal Drugs
- Anti Inflammation liposomal drugs
- Pain Management Liposomes
No
Drug
Global market size
1
Liposomal doxorubicin
Its market reached USD 1.2 billion in 2023, and it will reach up to USD 2.3 billion by 2033. Reflecting a compound annual growth rate (CAGR) = 6.7% (2024 to 2033).
2
Liposomal (Daunorubicin/cytarabine)
Its market reached USD 128 million in 2023 and it will reach USD 184 million by 2030. CAGR = 5.3%.
3
Cytarabine liposome injection
Its market reached USD 6 Billion in 2023 and it will reach USD 10.06 Billion by 2030. CAGR = 6.8% (2024 to 2030).
4
Liposomal mifamurtide
Its market reached USD 15 million in 2023 and it will reach USD 11 million by 2030. CAGR = -3.5%.
5
Vincristine sulfate in liposome
Its market reached USD 211 million in 2023 and it will reach USD 351.2 million by 2030. CAGR = 6.9% (2024 – 2030).
6
Liposomal irinotecan
Its market reached 36.9 M Euro in 2023 and will reach 47.3 M Euro by 2024.
No
Drug
Global market size
7
liposomal amphotericin B
USD 496 million in 2022 and USD 740.5 million by 2029. CAGR = 6.0% (2023 to 2029). Anti-inflammation liposomal drugs
No
Drug
Global market size
8
Liposomal verteporfin
Market value was over USD 244 billion in 2023
9
Liposomal Prednisolone
Prednisolone's market value was over USD 6 billion in 2023 and USD 9 billion by 2036. CAGR = 5% (2024-2036)
No
Drug
Global market size
10
Liposomal morphine
In general, the morphine market valued at 25.90 billion USD in 2021 and 27.89 billion USD in 2022. However, it will reach 50.49 billion USD by 2030. CAGR = 7.7% (2023- 2030).
11
Liposomal bupivacaine
It is barely new to the global market, and it reached 143.9 million USD in 2023 (a 4% increase over the $138.0 million USD of 2022).
